MOTS-c (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a short, 16-amino-acid peptide encoded within the mitochondrial genome and studied for its activity as a regulator of cellular energy balance. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound is handled and measured in research contexts, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of roughly 3.33 mg/mL (about 3,333 mcg/mL). At that fill, each 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers approximately 333 mcg of material, so a full 1 mg (1000 mcg) measurement corresponds to about 30 units, or 0.30 mL.

Standard (Gradual) Titration Schedule

The gradual schedule steps the daily amount up every two weeks, a slow ramp commonly used in research handling to model tolerability before reaching the upper end of the studied band.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, which keeps foaming to a minimum.
3. Swirl or gently roll the vial until the powder is fully dissolved. Do not shake; vigorous agitation can shear the peptide.
4. The solution should finish clear and colourless. Label the vial with the concentration (3.33 mg/mL) and the reconstitution date.
5. Refrigerate upright between uses and draw subsequent volumes with a fresh sterile syringe each time, ideally within about seven days.

Advanced (Maintenance) Schedule

Once the upper step has been reached on the gradual ramp, an advanced handling pattern holds the dose at the top of the studied band and cycles it, rather than escalating further. The 1 mg ceiling reflects the practical upper end of the daily research range for this fill.

Supplies Needed

• MOTS-c vials (10 mg): ~3 vials for an 8-week run; ~6 vials for 12 weeks; ~9 vials for a full 16-week cycle.
• Insulin syringes (U-100, 1 mL): roughly 56 for 8 weeks, 84 for 12 weeks and 112 for 16 weeks — one fresh syringe per daily draw.
• Bacteriostatic water (10 mL): one bottle for an 8-week run, two for 12 weeks, three for 16 weeks.
• Alcohol swabs: about 112 for 8 weeks, scaling to ~224 for a 16-week schedule (two per daily handling step).

Protocol Overview

• Research goal: model metabolic and mitochondrial energy regulation via AMPK signalling.
• Schedule: once-daily subcutaneous administration in the published research model.
• Dose band: 200–1000 mcg daily, titrated upward over roughly ten weeks.
• Fill: 10 mg lyophilized, reconstituted to 3.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted, used within ~7 days.

Dosing Protocol Notes

• Begin at the lowest 200 mcg step and hold each level for about two weeks before escalating.
• Keep administration on a fixed daily cadence — the same time of day where possible — for steady exposure modelling.
• Escalate only after tolerability appears stable at the prior step.
• The 600–1000 mcg band carries most of the metabolic signal reported in the preclinical literature.

Storage Instructions

Keep sealed lyophilized vials at −20 °C (−4 °F) or below, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C (about 36–46 °F) and use within roughly seven days; potency declines measurably over time in solution, with research notes citing on the order of a 25% activity loss after 24 hours at 4 °C for some preparations. Avoid repeated freeze-thaw cycles and let refrigerated solution warm slightly before drawing.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Handle the stopper gently and keep it intact across the many daily draws this schedule requires.
• Because MOTS-c is short-lived in solution, prepare only what a vial will use within its window rather than over-reconstituting.
• Document each draw — date, volume, remaining material — for reproducibility.

How MOTS-c Works

MOTS-c is a mitochondrial-derived peptide: it is encoded within the 12S ribosomal RNA region of the mitochondrial genome rather than in nuclear DNA. In research models it behaves like a metabolic stress signal that helps tune how cells generate and spend energy. Its best-characterised action is activation of the AMP-activated protein kinase (AMPK) pathway, reportedly via interference with the folate–methionine cycle, which shifts cells toward greater glucose uptake and fatty-acid oxidation. Under metabolic stress it can translocate to the nucleus and influence the expression of stress-response and antioxidant genes, linking mitochondrial status to broader cellular adaptation.

Reported Benefits & Side Effects

Findings observed in preclinical studies

• Improved insulin sensitivity and glucose handling in metabolic models.
• Resistance to diet-induced obesity and reductions in visceral and liver fat.
• Enhanced physical capacity — aged mice reportedly sustained treadmill exercise roughly twice as long after treatment.
• Supportive effects on cardiac function, bone-forming osteoblast activity and immune-aging markers.

Tolerability notes

• No adverse effects were reported across the published preclinical animal studies.
• Human tolerability and safety remain uncharacterised; there is no controlled human dosing data.
• Because MOTS-c influences energy metabolism, research handling treats glucose-related effects as the main variable to monitor in models.

Supporting Lifestyle Factors (Research Context)

• Exercise is a recurring co-variable — MOTS-c expression rises with physical activity, and study designs often pair the two.
• Caloric and nutrient context strongly shape the metabolic readouts, so diet is controlled in published models.
• Standard trial controls — sleep, hydration and stress management — are held steady to isolate the compound's effect.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them dry fully.
• Insert subcutaneously at roughly 90° (or 45° for lean tissue) depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly over a few seconds, then withdraw at the same angle.
• Rotate sites systematically — abdomen (about two inches from the navel), outer thighs and upper arms — and dispose of sharps in an approved container.

References

Related Protocols